Please refer to the attachment
GUJTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 5.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gujarat Themis Biosyn reported FY26 revenue of Rs 16,582.28 lakhs, up ~10% from Rs 15,080 lakhs in FY25. However, profit after tax declined 4.3% to Rs 4,668.15 lakhs from Rs 4,877.17 lakhs in the prior year. The company also faces margin pressure with EBITDA margin compression. Finance costs more than doubled to Rs 294.89 lakhs from Rs 36.40 lakhs, contributing to the profit decline. Borrowings increased significantly from Rs 2,989 lakhs to Rs 12,997.55 lakhs. The board recommended a dividend of Rs 0.67 per share and approved a preferential issue of equity shares to non-promoters. The statutory auditor gave an unmodified (clean) opinion on the financial results.
Revenue growth of ~10% is positive but the PAT decline and margin compression may concern investors. Significant increase in debt levels warrants monitoring. The preferential issue will dilute existing shareholders' stakes.